Navigation Links
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Date:4/1/2008

n this population of patients with coronary artery disease, which included nearly 1,100 patients with prior heart failure. Ranolazine had no effect on the risk of CV death or MI in the study.

About Angina

Chronic angina is a serious and debilitating heart condition, usually associated with coronary artery disease and marked by repeated and sometimes unpredictable attacks of chest pain. Approximately 8.9 million people in the United States have chronic angina, and 400,000 new cases are diagnosed annually, according to the American Heart Association. Ranexa has anti- ischemic effects which do not depend on changes in heart rate or blood pressure.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject t
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
2. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
3. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
4. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
5. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
6. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
7. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
10. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
11. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 Decision Resources, one of the ... and healthcare issues, finds that the cost of ... and side-effect profile, are cited most frequently by ... of Avastin for non-small-cell lung cancer treatment in ... ,, The new Special European Physician & Payer ...
(Date:12/17/2009)... HUNTINGTON BEACH, California and AMSTERDAM, December 17 /PRNewswire/ ... announced today that,the US Food and Drug Administration ... all ages. MammaPrint is the only FDA-cleared,breast cancer ... the,past three years, the FDA has issued four ... service. , "This FDA ...
(Date:12/17/2009)... Calif., Dec. 17 Frost & ... North American Healthcare Innovation Award in molecular ... for its commitment to providing innovative technologies ... Since its incorporation in 2004, IntelligentMDx has ... approach to make tests that are clinically ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3FDA Broadens Clearance for Agendia's MammaPrint(R) 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 2Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 3Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 4Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics 5More Gene Mutations Linked to Autism Risk 4655 1More Gene Mutations Linked to Autism Risk 4655 2More Gene Mutations Linked to Autism Risk 4655 3More Gene Mutations Linked to Autism Risk 4655 4HIV Testing Day Set for Saturday in U S 50162 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 1Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 2Bausch 26 Lomb Vision Care Strengthens Its Commitment to ReNu 28R 29 Brand and the Eye Care Community 50159 3
... EPOC Results Published in March 22 Issue ... March 20 Sanofi-aventis,today announced that efficacy ... Intergroup study published in the March 22 ... patients Eloxatin(R) (oxaliplatin injection) in,combination with 5-fluorouracil/leucovorin ...
... targeting interleukin-6 receptors, ACTEMRA provides significant ... existing therapies -, NUTLEY, N.J., March 20 ... (tocilizumab) experienced,significant and rapid reduction in the signs ... published in this week,s issue of The Lancet. ...
Other Medicine Technology:Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 2International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 3International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 4International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet 5
(Date:12/17/2009)... Today, SEIU ULTCW (United Long Term Care Workers, ... (IHSS) providers have overwhelmingly voted in favor of ... multiple layers of protection to the current homecare ... granting additional contract improvements. ,, "As several ... homecare provider wages to as low as minimum ...
(Date:12/17/2009)... Racial and ethnic disparities in cancer survival ... early and treated successfully, including breast and prostate ... Columbia University,s Mailman School of Public Health and ... University Medical Center/NewYork-Presbyterian Hospital. Disparities are small ... early detection and treatment options, such as pancreatic ...
(Date:12/17/2009)... phone use in era of sexually explicit messaging, experts ... Teens and preteens spend hours sending text messages from ... those messages -- sexually explicit material, giving the messaging ... parents, University of Michigan researchers report. , In fact, ... parents are worried about the time their children spend ...
(Date:12/17/2009)... doses delivered during computed tomography examinations underscore the important ... dose and protecting patients, according to the American Society ... ... Albuquerque, NM (Vocus) December 16, 2009 -- ... tomography examinations underscore the important role that competent, educated ...
(Date:12/17/2009)... Dec. 17 Motionsoft, Inc. announced today ... Card Industry (PCI) Data Security Standards (DSS) certification, ... software vendors in the health and wellness space ... PCI Standard is the result of a collaborative ... companies (Visa International, MasterCard Worldwide, American Express, Discover ...
Breaking Medicine News(10 mins):Health News:New Alameda County IHSS Contract Sends Clear Message to Elected Leaders That Homecare Program Must Remain a California Priority 2Health News:Cancer survival disparities for most minority populations increase as cancers become more treatable 2Health News:'Sexting' by Kids Begets Fretting by Parents 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 2Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 3Health News:ASRT Supports Efforts to Minimize CT Radiation Dose 4Health News:Motionsoft Completes PCI Compliance Certification 2
... of sources in the environment and from industry and ... via the diet and drinking water. In chronic exposure, ... kidneys and the liver. The liver acts as a ... gastrointestinal tract and liver cells can be exposed to ...
... struggling at home almost every day , WEDNESDAY, Jan. 16 ... can occur daily and is much more severe than previously ... who kept diaries to record daily pain and whether they ... pain. , "The major finding of our study was that ...
... Every year, 759,000 children with asthma may be at risk ... insurance. About 30 percent of those families earn more than ... the threshold for the state childrens health insurance program in ... are without insurance at some point during the year, said ...
... to Signal Commitment to,Health of Babies, WHITE PLAINS, N.Y., ... brought in $117 million,nationwide last year, has been renamed March ... the March of Dimes is all about -- the health ... our mission stays the same --,working towards the day when ...
... On January 14, Dr. Judah,Folkman, founder of the field ... to Vancouver for one of the thousands of lectures,that ... and scientific,pioneer, Dr. Folkman was founder and director of ... professor of Pediatric Surgery,and Cell Biology at Harvard Medical ...
... had 47% higher risk of cardiovascular trouble , , TUESDAY, ... by millions of postmenopausal women to reduce their risk ... heart attack and other cardiovascular problems. , The findings ... , "There are data from other recent studies showing ...
Other Medicine News:Health News:Sickle Cell Patients in More Pain Than Thought 2Health News:759,000 children with asthma endure gaps in insurance every year 2Health News:WalkAmerica Is Now March for Babies 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 2Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 3Health News:Children's Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis 4Health News:Calcium Supplements Could Raise Heart Risks in Postmenopausal Women 2Health News:Calcium Supplements Could Raise Heart Risks in Postmenopausal Women 3Health News:Calcium Supplements Could Raise Heart Risks in Postmenopausal Women 4
... SonoVue, a new Contrast ... aqueous suspension of stabilized SF6 ... microbubbles is between 1 and ... is between 2 and 5 ...
... well-established, second-generation ultrasound medical diagnostic product with ... borders of the heart. This allows doctors ... the heart during an ultrasound scanning procedure, ... heart condition and providing guidance for the ...
... new tibial guide is designed for accuracy ... choose between "point" or "elbow" aimers and ... creation of the tibial tunnel. The system ... features and the reproducibility and accuracy gained ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Medicine Products: